Bristol-Myers Squibb announces U.S. FDA approval of an additional indication for Opdivo (nivolumab)
Posted: 5 March 2015 |
Bristol-Myers Squibb Company announced an approval of an additional indication for Opdivo (nivolumab) by the U.S. Food and Drug Administration…
Bristol-Myers Squibb Company (NYSE:BMY) have announced an approval of an additional indication for Opdivo (nivolumab) by the U.S. Food and Drug Administration.
Please see full Prescribing Information available at www.bms.com.
The company will provide additional details on the approval in a press release to follow.
Related organisations
Bristol-Myers Squibb Company, Food and Drug Administration (FDA)
